← Back to Search

Intraocular Lens

enVista MX60EF for Cataract

N/A
Waitlist Available
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 120 to day 180 after second eye implantation
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of a new type of intraocular lens for people with cataracts.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 120 to day 180 after second eye implantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 120 to day 180 after second eye implantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Photopic monocular best-corrected distance visual acuity (BCDVA)
Photopic monocular distance-corrected intermediate visual acuity (DCIVA)
Photopic monocular distance-corrected near visual acuity (DCNVA)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: enVista MX60EFExperimental Treatment1 Intervention
enVista MX60EF (trifocal) multifocal IOL (MIOL)
Group II: enVista MX60EActive Control1 Intervention
enVista MX60E monofocal IOL
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
enVista MX60EF
2018
N/A
~510

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor
251 Previous Clinical Trials
56,918 Total Patients Enrolled
47 Trials studying Cataract
15,502 Patients Enrolled for Cataract
Anya LoncaricStudy DirectorBausch health companies
39 Previous Clinical Trials
20,330 Total Patients Enrolled
5 Trials studying Cataract
1,751 Patients Enrolled for Cataract
~72 spots leftby Jun 2025